Table 2.

Effect of Menhaden oil dietary enrichment or daily treatment with resolvin D1, E1, D1 methyl ester or D2 methyl ester of diabetic mice on change in body weight, blood glucose and serum triglycerides, free fatty acids, cholesterol, resolvin D1 and thiobarbituric acid levels and liver proteasome activity and steatosis (Data are presented as the mean ± S.E.M.

Determination	Control (I)	Diabetic (II)	Diabetic+Menhaden Oil (III)	Diabetic+Res D1 (IV)	Diabetic+Res E (V)	Diabetic+Res D1 ME (VI)	Diabetic +Res D2 ME (VII)
	−12	−12	−12	−12	−11	−11	−11
Start weight (g)	25.7 ± 0.4	26.6 ± 0.4	26.5 ± 0.5	26.9 ± 0.4	25.9 ± 0.4	27.1 ± 0.5	25.1 ± 0.5
Weight at Treatment (g)	31.2 ± 0.4	40.7 ± 1.8a	38.4 ± 2.1	41.8 ± 2.3a	37.2 ± 2.1	40.2 ± 2.0a	37.7 ± 1.9
Final weight (g)	33.5 ± 0.6	48.3 ± 3.0a	42.5 ± 2.8	46.3 ± 2.9a	40.1 ± 3.3	45.6 ± 3.4	40.2 ± 3.4
Blood glucose at Treatment (mg/dL)	139 ± 11	328 ± 27a	352 ± 33a	351 ± 28a	338 ± 37a	332 ± 25a	397 ± 23a
Final Blood glucose (mg/dL)	211 ± 7	416 ± 34a	405 ± 38a	375 ± 45a	380 ± 41a	357 ± 44a	443 ± 46a
Triglycerides (mg/dL)	62 ± 9	100 ± 15	56 ± 8b	61 ± 8	58 ± 14	50 ± 6b	56 ± 4b
Free fatty acids (mmol/L)	0.44 ± 0.03	0.76 ± 0.14a	0.30 ± 0.03b	0.35 ± 0.02b	0.37 ± 0.06b	0.44 ± 0.07b	0.42 ± 0.05b
Cholesterol (mg/mL)	1.60 ± 0.09	2.91 ± 0.21a	3.08 ± 0.12a	2.22 ± 0.23	2.09 ± 0.24	2.34 ± 0.21	2.64 ± 0.23a
Resolvin D1 (pg/mL)	363 ± 46	396 ± 25	583 ± 72a,b	ND	ND	ND	ND
Thiobarbituric acid (mg/mL)	0.74 ± 0.05	1.07 ± 0.08a	1.18 ± 0.09a	0.83 ± 0.07	0.88 ± 0.07	0.94 ± 0.10	0.99 ± 0.03
Liver proteasome activity (U/mg protein)	0.288 ± 0.003	0.199 ± 0.008a	0.244 ± 0.006a,b	0.226 ± 0.009a	0.215 ± 0.013a	0.215 ± 0.009a	0.243 ± 0.010a,b
Steatosis (% area)	6.7 ± 0.7	57.0 ± 2.2a	32.2 ± 1.4a,b	40.3 ± 1.8a,b	30.2 ± 2.6a,b	28.2 ± 2.0a,b	36.5 ± 1.4a,b

^aP<0.05 compared to control mice;

^bP<0.05 compared to diabetic mice.

ND: Not Determined. Parentheses indicate number of experimental).